Reuters -- Keryx Biopharmaceuticals Inc said a mid-stage trial showed its colon cancer drug improved overall survival in heavily pre-treated patients with advanced metastatic colon cancer, as compared with a dummy drug, sending its shares up 13 percent in premarket trade.
